Compare Abeona Therapeutics Inc (ABEO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Abeona Therapeutics Inc trades at $6.77 (market cap $373.32M), while Vertex Pharmaceuticals Incorporated trades at $503.92 (market cap $132.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 355.1× Abeona Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| ABEO | VRTX | |
|---|---|---|
Market Cap | $373.32M | $132.55B |
Sector | Health | Health |
52-Week High | $7.23 | $529.59 |
52-Week Low | $4.17 | $366.54 |
Enterprise Value | $228.22M | $127.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Vertex Pharmaceuticals (VRTX) trades at $522.25, down 1.1% on the day but remains near its all-time high. The stock shows strong fundamentals with 35.5% net income margins and robust cash flow generation. Recent developments include a $10 billion acquisition of Crinetics Pharmaceuticals and FDA approval for expanded use of its gene therapy CASGEVY in younger patients. Technical indicators show bullish moving averages but overbought oscillators with RSI readings above 89.
The outlook remains positive with 84% analyst buy ratings and a consensus price target of $522. Key catalysts include the Crinetics acquisition's $5 billion peak sales potential and continued gene therapy expansion. Risks include integration challenges from the major acquisition and potential regulatory hurdles. The stock trades at premium valuations (P/E 31.4) but justifies this with strong profitability and growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
